Company

Botanix Pharmaceuticals Limited

Headquarters: North Perth, WA, Australia

Employees: 6

ASX: BOT

Market Cap

A$615.1 Million

AUD as of July 1, 2024

US$409.7 Million

Market Cap History

Botanix Pharmaceuticals Limited market capitalization over time

Evolution of Botanix Pharmaceuticals Limited market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Botanix Pharmaceuticals Limited

Detailed Description

Botanix Pharmaceuticals Limited, a clinical stage synthetic cannabinoid pharmaceutical company, engages in the research and development of dermatology and antimicrobial products in Australia. Its product pipeline include BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase Ib clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in North Perth, Australia.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Botanix Pharmaceuticals Limited has the following listings and related stock indices.


Stock: ASX: BOT wb_incandescent

Details

Headquarters:

50 Angove Street

Level 1

North Perth, WA 6006

Australia

Phone: 61 8 6555 2945

Fax: 61 8 6210 1153